Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma

Amani Makkouk, Xue Yang, Taylor Barca, Anthony Lucas, Mustafa Turkoz, Jonathan T S Wong, Kevin Nishimoto, Mary M. Brodey, M. Tabrizizad, Smitha Gundurao,

Journal for ImmunoTherapy of Cancer · 2021 · 171 citations · 24 references

DOIFull text

Open access

Abstract

Expanded Vδ1 T cells engineered with a GPC-3 CAR and sIL-15 represent a promising platform warranting further clinical evaluation as an off-the-shelf treatment of HCC and potentially other GPC-3-expressing solid tumors.

References

24